Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. Its flagship research and development programs are focused on advancing formulations to significantly improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders. The company was founded by Richard Greenberg on November 10, 1952 and is headquartered in Glendale, CO.